Anti-inflammatory Effects of Rosuvastatin in Patients with Chronic Kidney Diseases_West China Medical Journal

Authors：

WANG Guohua ,  ZHANG Xu , CAO Juan , LI Haitao , YIN Di , ZHOU Changju , XU Qin , DING Hao , ZHAO Caixia

Department of Nephrology, Taixing Hospital Affiliated to Yangzhou University, Taixing, Jiangsu 225400, P. R. China;

Corresponding author：

ZHANG Xu, Email: wangguohua0403@126.com

Keywords：

瑞舒伐他汀; 慢性肾病; 炎症

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【摘要】　目的　探讨瑞舒伐他汀对慢性肾病患者抗炎疗效。　方法　选取2009年11月-2010年12月90例慢性肾病患者，随机分为A、B两组，A组50例，给予瑞舒伐他汀钙10 mg/d；B组40例，给予阿托伐他汀钙10 mg/d，两组患者的年龄和性别相匹配。分别测定其治疗前及治疗后12周时血白细胞、高敏反应蛋白、纤维蛋白原、白介素-6、肿瘤坏死因子-α。　结果　两组治疗前各炎症指标水平差异无统计学意义（P gt;0.05）。与治疗前相比，两组患者治疗12周后炎症指标水平均较前明显下降（P lt;0.01），瑞舒伐他汀钙组比阿托伐他汀钙组炎症指标下降更为明显。　结论　瑞舒伐他汀可有效改善慢性肾病患者的炎症反应。
【Abstract】　Objective　 To explore the anti-inflammatory effect of rosuvastatin on chronic kidney disease (CKD) patients. 　Methods　 Ninety CKD patients treated in our hospital between November 2009 and December 2010 were randomly divided into two groups. One group was given rosuvastatin calcium 10 mg/d, which the other group was given atorvastatin calcium 10 mg/d. The two groups matched in terms of age and gender. We determined blood leukocyte (WBC), high sensitivity reactive protein (hs-CRP), fibrinogen (FIG), interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) of the patients before and after treatment for 12 weeks.　Results　 The inflammatory marker levels of both groups before treatment had no significant difference (P gt;0.05). The inflammatory marker levels of two groups after treatment for 12 weeks were significantly decreased compared with the levels before treatment (P lt;0.01), and rosuvastatin calcium group decreased more apparently than atorvastatin calcium group.　Conclusion　 Rosuvastatin can improve the anti-inflammatory response in CKD patients.

Citation： WANG Guohua,ZHANG Xu,CAO Juan,LI Haitao,YIN Di,ZHOU Changju,XU Qin,DING Hao,ZHAO Caixia. Anti-inflammatory Effects of Rosuvastatin in Patients with Chronic Kidney Diseases. West China Medical Journal, 2011, 26(9): 1287-1289. doi: Copy

1.	Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients[J]. Kidney Int, 2002, 18(8): 1452-1455.
2.	Dimitrow PP, Jawień M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia[J]. Pharmacological Rep, 2010, 62(6): 1250-1254.
3.	März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1316-1325.
4.	Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg,rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism[J]. J Cardiovasc Pharmacol Ther, 2010, 15(2): 167-174.
5.	Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J]. Circulation, 2003, 107(1): 87-92.
6.	Recio-mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease:a cross-sectional study of predialysis, dialysis and kidney-transplantation patients[J]. Atherosclerosis, 2011, 216(2): 446-451.
7.	Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease[J]. J Ren Care, 2011, 37(1): 12-15.
8.	Michel C, Giuseppe L, Martina M, et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis[J]. Nephrol Dial Transplant, 2008, 23(9): 2879-2883.
9.	Ross R. Atrheroselerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
10.	王海燕. 肾脏病学[M]. 3版. 北京: 人民卫生出版社, 2008: 1886-1892.
11.	Goldsmith D, Covic AC. Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD[J]. Int Urol Nephrol, 2010, 42(1): 133-136.
12.	李秋荣, 王勤, 曲环, 等. 瑞舒伐他汀对血脂正常的2型糖尿病患者血清高敏C反应蛋白的作用[J]. 中华高血压杂志, 2011, 19(3): 280-282.
13.	严庆场, 吴广华. 瑞舒伐他汀对急性冠脉综合征患者CRP, LOX-1的影响[J].中华全科医学, 2011, 9(4): 581-632.
14.	Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein[J]. J Nephrol, 2009, 22(1): 83-89.
15.	Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease[J]. Am J Cardiol, 2005, 96(9): 1290-1292.
16.	Gómez-García A, Martínez Torres G, Ortega-Pierres LE, et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol, 2007, 60(12): 1242-1249.
17.	Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21): 2195-2207.
18.	Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia[J]. Pharm Res, 2009, 26(4): 958-964.

1. 　Wanner C, Zimmermann J, Schwedler S, et al. Inflammation and cardiovascular risk in dialysis patients[J]. Kidney Int, 2002, 18(8): 1452-1455.
2. 　Dimitrow PP, Jawień M. Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia[J]. Pharmacological Rep, 2010, 62(6): 1250-1254.
3. 　März W, Genser B, Drechsler C, et al. Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis[J]. Clin J Am Soc Nephrol, 2011, 6(6): 1316-1325.
4. 　Her AY, Kim JY, Kang SM, et al. Effects of atorvastatin 20 mg,rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism[J]. J Cardiovasc Pharmacol Ther, 2010, 15(2): 167-174.
5. 　Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency[J]. Circulation, 2003, 107(1): 87-92.
6. 　Recio-mayoral A, Banerjee D, Streather C, et al. Endothelial dysfunction, inflammation and atherosclerosis in chronic kidney disease:a cross-sectional study of predialysis, dialysis and kidney-transplantation patients[J]. Atherosclerosis, 2011, 216(2): 446-451.
7. 　Zyga S, Christopoulou G, Malliarou M. Malnutrition-inflammation-atherosclerosis syndrome in patients with end-stage renal disease[J]. J Ren Care, 2011, 37(1): 12-15.
8. 　Michel C, Giuseppe L, Martina M, et al. Association of inflammation with anaemia in patients with chronic kidney disease not requiring chronic dialysis[J]. Nephrol Dial Transplant, 2008, 23(9): 2879-2883.
9. 　Ross R. Atrheroselerosis-an inflammatory disease[J]. N Engl J Med, 1999, 340(2): 115-126.
10. 　王海燕. 肾脏病学[M]. 3版. 北京: 人民卫生出版社, 2008: 1886-1892.
11. 　Goldsmith D, Covic AC. Jupiter or Aurora? Micro-inflammation and dyslipidaemia: twin targets for statin therapy in CKD[J]. Int Urol Nephrol, 2010, 42(1): 133-136.
12. 　李秋荣, 王勤, 曲环, 等. 瑞舒伐他汀对血脂正常的2型糖尿病患者血清高敏C反应蛋白的作用[J]. 中华高血压杂志, 2011, 19(3): 280-282.
13. 　严庆场, 吴广华. 瑞舒伐他汀对急性冠脉综合征患者CRP, LOX-1的影响[J].中华全科医学, 2011, 9(4): 581-632.
14. 　Burmeister JE, Miltersteiner DR, Campos BM. Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein[J]. J Nephrol, 2009, 22(1): 83-89.
15. 　Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease[J]. Am J Cardiol, 2005, 96(9): 1290-1292.
16. 　Gómez-García A, Martínez Torres G, Ortega-Pierres LE, et al. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia[J]. Rev Esp Cardiol, 2007, 60(12): 1242-1249.
17. 　Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. N Engl J Med, 2008, 359(21): 2195-2207.
18. 　Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids, inflammatory markers and adiponectin in patients with hypercholesterolemia[J]. Pharm Res, 2009, 26(4): 958-964.

West China Medical Journal

Anti-inflammatory Effects of Rosuvastatin in Patients with Chronic Kidney Diseases

Abstract Full text Figures/Tables Video References Cited by

Format

Content